Open Beta
TREN
MetriLume
TREN

US marketsPVCT

SEC-sourced researchBeta

PVCT

PROVECTUS BIOPHARMACEUTICALS, INC.

Company comparison ↗

Data passport

CIK
0000315545
Exchange
OTC
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 5, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 617,140.0000 USD; December 2025: 336,108.0000 USD617.1K USD0 USD0December 2024December 2025
PVCT · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2024617,140.0000Mar 26, 2026
December 2025336,108.0000Mar 26, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025336,108.0000-5,430,851.0000-3,325,991.0000697,502.00007,000,220.0000Mar 26, 2026
December 2024617,140.0000-4,732,552.0000-3,284,091.00001,006,259.00006,975,484.0000Mar 26, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$336.11KDecember 2025Mar 26, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$617.14KDecember 2024Mar 26, 202610-K
Net incomeNetIncomeLoss-$5.43MDecember 2025Mar 26, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$3.33MDecember 2025Mar 26, 202610-K
Total assetsAssets$697.5KDecember 2025Mar 26, 202610-K
Total liabilitiesLiabilities$7MDecember 2025Mar 26, 202610-K

New filings

Explore methodology ↗